{"id":"https://openalex.org/W2142756331","doi":"https://doi.org/10.1192/bjp.179.6.514","title":"Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder","display_name":"Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder","publication_year":2001,"publication_date":"2001-12-01","ids":{"openalex":"https://openalex.org/W2142756331","doi":"https://doi.org/10.1192/bjp.179.6.514","mag":"2142756331","pmid":"https://pubmed.ncbi.nlm.nih.gov/11731354"},"language":"en","primary_location":{"id":"doi:10.1192/bjp.179.6.514","doi":"https://doi.org/10.1192/bjp.179.6.514","is_oa":true,"landing_page_url":"https://doi.org/10.1192/bjp.179.6.514","pdf_url":"https://www.cambridge.org/core/services/aop-cambridge-core/content/view/6847B8CE621A8AFC3BB3E342EFBF49C1/S0007125000160064a.pdf/div-class-title-efficacy-of-usual-antidepressant-dosing-regimens-of-fluoxetine-in-panic-disorder-div.pdf","source":{"id":"https://openalex.org/S127936299","display_name":"The British Journal of Psychiatry","issn_l":"0007-1250","issn":["0007-1250","1472-1465"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311721","host_organization_name":"Cambridge University Press","host_organization_lineage":["https://openalex.org/P4310311721","https://openalex.org/P4310311702"],"host_organization_lineage_names":["Cambridge University Press","University of Cambridge"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Psychiatry","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://www.cambridge.org/core/services/aop-cambridge-core/content/view/6847B8CE621A8AFC3BB3E342EFBF49C1/S0007125000160064a.pdf/div-class-title-efficacy-of-usual-antidepressant-dosing-regimens-of-fluoxetine-in-panic-disorder-div.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5064619641","display_name":"David Michelson","orcid":"https://orcid.org/0009-0005-5804-1424","observed_orcids":["https://orcid.org/0009-0005-5804-1424"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"D. Michelson","raw_affiliation_strings":["Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA","Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA","institution_ids":["https://openalex.org/I168537998"]},{"raw_affiliation_string":"Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068499328","display_name":"Christer Allgulander","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. Allgulander","raw_affiliation_strings":["Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017106064","display_name":"Karl Dantendorfer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"K. Dantendorfer","raw_affiliation_strings":["Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007961490","display_name":"Aleksandar Kne\u017eevi\u0107","orcid":"https://orcid.org/0000-0002-2776-9675","observed_orcids":["https://orcid.org/0000-0002-2776-9675","https://orcid.org/0000-0002-9297-793X"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. Knezevic","raw_affiliation_strings":["Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061774425","display_name":"Dagmar Maierhofer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D. Maierhofer","raw_affiliation_strings":["Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079981946","display_name":"V. Micev","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"V. Micev","raw_affiliation_strings":["Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067694199","display_name":"V.R. Paunovi\u0107","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"V. R. Paunovic","raw_affiliation_strings":["Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020037072","display_name":"I. Timotijevi\u0107","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"I. Timotijevic","raw_affiliation_strings":["Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027169785","display_name":"Neena Sarkar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"N. Sarkar","raw_affiliation_strings":["Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":null,"display_name":"L. Skoglund","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"L. Skoglund","raw_affiliation_strings":["Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"last","author":{"id":null,"display_name":"S. C. Pemberton","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. C. Pemberton","raw_affiliation_strings":["Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA","institution_ids":["https://openalex.org/I168537998"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5064619641"],"corresponding_institution_ids":["https://openalex.org/I168537998"],"apc_list":{"value":4920,"currency":"USD","value_usd":4920},"apc_paid":null,"fwci":2.9837,"has_fulltext":true,"cited_by_count":62,"citation_normalized_percentile":{"value":0.91256712,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"179","issue":"6","first_page":"514","last_page":"518"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10853","display_name":"Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes","score":0.9932000041007996,"subfield":{"id":"https://openalex.org/subfields/3205","display_name":"Experimental and Cognitive Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T10853","display_name":"Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes","score":0.9932000041007996,"subfield":{"id":"https://openalex.org/subfields/3205","display_name":"Experimental and Cognitive Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.0027000000700354576,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10786","display_name":"Maternal Mental Health During Pregnancy and Postpartum","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/fluoxetine","display_name":"fluoxetine","score":0.9700000286102295},{"id":"https://openalex.org/keywords/panic-disorder","display_name":"panic disorder","score":0.9990000128746033},{"id":"https://openalex.org/keywords/serotonin-reuptake-inhibitors","display_name":"serotonin reuptake inhibitors","score":0.7870000004768372},{"id":"https://openalex.org/keywords/panic-attacks","display_name":"panic attacks","score":0.6549999713897705},{"id":"https://openalex.org/keywords/treatment-efficacy","display_name":"treatment efficacy","score":0.5460000038146973},{"id":"https://openalex.org/keywords/placebo-controlled-comparison","display_name":"placebo comparison","score":0.42500001192092896}],"concepts":[{"id":"https://openalex.org/C2776134451","wikidata":"https://www.wikidata.org/wiki/Q422244","display_name":"Fluoxetine","level":4,"score":0.951949954032898},{"id":"https://openalex.org/C2777529043","wikidata":"https://www.wikidata.org/wiki/Q741713","display_name":"Panic disorder","level":3,"score":0.8335304260253906},{"id":"https://openalex.org/C2779177272","wikidata":"https://www.wikidata.org/wiki/Q76560","display_name":"Antidepressant","level":3,"score":0.730402946472168},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.7063999176025391},{"id":"https://openalex.org/C2780712732","wikidata":"https://www.wikidata.org/wiki/Q208450","display_name":"Panic","level":3,"score":0.6467927694320679},{"id":"https://openalex.org/C2780092697","wikidata":"https://www.wikidata.org/wiki/Q7455053","display_name":"Serotonin reuptake inhibitor","level":4,"score":0.5161015391349792},{"id":"https://openalex.org/C2777669559","wikidata":"https://www.wikidata.org/wiki/Q407617","display_name":"Sertraline","level":4,"score":0.5120533108711243},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5059520602226257},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.45008012652397156},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.4423530101776123},{"id":"https://openalex.org/C2776317618","wikidata":"https://www.wikidata.org/wiki/Q544006","display_name":"Anxiety disorder","level":3,"score":0.4155175983905792},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.3849857747554779},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.3616122007369995},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.35538655519485474},{"id":"https://openalex.org/C2775864247","wikidata":"https://www.wikidata.org/wiki/Q167934","display_name":"Serotonin","level":3,"score":0.3161216378211975},{"id":"https://openalex.org/C558461103","wikidata":"https://www.wikidata.org/wiki/Q154430","display_name":"Anxiety","level":2,"score":0.18108195066452026},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005473","descriptor_name":"Fluoxetine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D005473","descriptor_name":"Fluoxetine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011569","descriptor_name":"Psychiatric Status Rating Scales","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016037","descriptor_name":"Single-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016584","descriptor_name":"Panic Disorder","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D018687","descriptor_name":"Antidepressive Agents, Second-Generation","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D018687","descriptor_name":"Antidepressive Agents, Second-Generation","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1192/bjp.179.6.514","doi":"https://doi.org/10.1192/bjp.179.6.514","is_oa":true,"landing_page_url":"https://doi.org/10.1192/bjp.179.6.514","pdf_url":"https://www.cambridge.org/core/services/aop-cambridge-core/content/view/6847B8CE621A8AFC3BB3E342EFBF49C1/S0007125000160064a.pdf/div-class-title-efficacy-of-usual-antidepressant-dosing-regimens-of-fluoxetine-in-panic-disorder-div.pdf","source":{"id":"https://openalex.org/S127936299","display_name":"The British Journal of Psychiatry","issn_l":"0007-1250","issn":["0007-1250","1472-1465"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311721","host_organization_name":"Cambridge University Press","host_organization_lineage":["https://openalex.org/P4310311721","https://openalex.org/P4310311702"],"host_organization_lineage_names":["Cambridge University Press","University of Cambridge"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Psychiatry","raw_type":"journal-article"},{"id":"pmid:11731354","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11731354","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The British journal of psychiatry : the journal of mental science","raw_type":"Clinical Trial"}],"best_oa_location":{"id":"doi:10.1192/bjp.179.6.514","doi":"https://doi.org/10.1192/bjp.179.6.514","is_oa":true,"landing_page_url":"https://doi.org/10.1192/bjp.179.6.514","pdf_url":"https://www.cambridge.org/core/services/aop-cambridge-core/content/view/6847B8CE621A8AFC3BB3E342EFBF49C1/S0007125000160064a.pdf/div-class-title-efficacy-of-usual-antidepressant-dosing-regimens-of-fluoxetine-in-panic-disorder-div.pdf","source":{"id":"https://openalex.org/S127936299","display_name":"The British Journal of Psychiatry","issn_l":"0007-1250","issn":["0007-1250","1472-1465"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311721","host_organization_name":"Cambridge University Press","host_organization_lineage":["https://openalex.org/P4310311721","https://openalex.org/P4310311702"],"host_organization_lineage_names":["Cambridge University Press","University of Cambridge"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Psychiatry","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"score":0.8199999928474426,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2142756331.pdf","grobid_xml":"https://content.openalex.org/works/W2142756331.grobid-xml"},"referenced_works_count":22,"referenced_works":["https://openalex.org/W270712350","https://openalex.org/W590310416","https://openalex.org/W1607171655","https://openalex.org/W1965927906","https://openalex.org/W1967304046","https://openalex.org/W1990323752","https://openalex.org/W2010759906","https://openalex.org/W2016646281","https://openalex.org/W2042167308","https://openalex.org/W2042791643","https://openalex.org/W2049489184","https://openalex.org/W2057929474","https://openalex.org/W2086201863","https://openalex.org/W2086678059","https://openalex.org/W2094918976","https://openalex.org/W2114613490","https://openalex.org/W2139596642","https://openalex.org/W2146490418","https://openalex.org/W2157064632","https://openalex.org/W2159011576","https://openalex.org/W3027989701","https://openalex.org/W3090293687"],"related_works":["https://openalex.org/W2042167308","https://openalex.org/W2415624480","https://openalex.org/W2073424974","https://openalex.org/W1560455169","https://openalex.org/W2094918976","https://openalex.org/W7213632052","https://openalex.org/W2054387447","https://openalex.org/W2056310730","https://openalex.org/W1990323752","https://openalex.org/W2357320013"],"abstract_inverted_index":{"BACKGROUND:":[0],"Although":[1],"serotonin":[2],"reuptake":[3],"inhibitors":[4],"are":[5,18],"effective":[6,20],"in":[7,37,136],"panic":[8,22,40,45,140],"disorder,":[9],"questions":[10],"concerning":[11],"whether":[12],"doses":[13],"associated":[14,104],"with":[15,44,105,115],"antidepressant":[16,33],"efficacy":[17,29],"also":[19],"for":[21,59,89],"disorder":[23,46],"remain.":[24],"AIMS:":[25],"To":[26],"assess":[27],"the":[28,31],"of":[30,35,95,98,111,128,139],"usual":[32],"dose":[34,90,127,158],"fluoxetine":[36,53,99],"treating":[38],"full":[39],"attacks.":[41],"METHOD:":[42],"Patients":[43,142],"were":[47,87],"randomised":[48],"to":[49,52,65,82,92,145],"placebo":[50,116],"or":[51],"initiated":[54],"at":[55,121,125,150],"10":[56],"mg":[57,67,97,130,152],"daily":[58,131,153],"1":[60],"week":[61],"and":[62,120,134],"then":[63],"increased":[64],"20":[66,129,151],"daily.":[68,100],"The":[69],"trial":[70],"lasted":[71],"12":[72],"weeks,":[73],"but":[74],"after":[75,117],"6":[76,118],"weeks":[77,119],"patients":[78,113],"who":[79,143],"had":[80],"failed":[81],"achieve":[83],"a":[84,93,106,126,147],"satisfactory":[85,148],"response":[86,149],"eligible":[88],"escalation":[91],"maximum":[94],"60":[96],"RESULTS:":[101],"Fluoxetine":[102,124],"was":[103],"statistically":[107],"significantly":[108],"greater":[109],"proportion":[110],"panic-free":[112],"compared":[114],"end-point.":[122],"CONCLUSIONS:":[123],"is":[132],"safe":[133],"efficacious":[135],"reducing":[137],"symptoms":[138],"disorder.":[141],"fail":[144],"obtain":[146],"may":[154],"benefit":[155],"from":[156],"further":[157],"increases.":[159]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2024,"cited_by_count":6},{"year":2023,"cited_by_count":2},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":6},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":2},{"year":2012,"cited_by_count":4}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}